Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2017

View Archived Issues

EMA committee recommends orphan drug designation for MK-0677

GABA(A) positive allosteric modulator shows promise in irritable bowel syndrome model

Bioverativ to acquire True North Therapeutics and obtain worldwide rights to TNT-009

European Commission grants marketing authorization for Axumin

Pfizer gene therapy granted U.S. orphan designation for Duchenne muscular dystrophy

Ninlaro capsules become available in Japan for the treatment of multiple myeloma

Preliminary results show nearly 100% immune response rates in clinical study of Pennvax-GP

miRagen Therapeutics' MRG-106 named orphan medicinal product in E.U.

Liquidia Technologies reports positive results from phase I study of LIQ-865

RDX-8940, an improved GPBAR1 agonist for treating NAFLD/NASH

FDA committee recommends approval of Endari for sickle cell disease

FDA awards fast track designation to CM-4620 for acute pancreatitis

Radius Health reports topline results from Tymlos extension trial

FDA committee recommends approval of neratinib in HER2-positive breast cancer

HitGen forms drug discovery collaboration with Scripps Research Institute and Calibr

Aronora initiates phase I study of xisomab 3G3

EMA awards orphan drug designation to Actinium's Actimab-A

T-cell differentiation antigen CD6, a potential target for treating multiple sclerosis

ProtoKinetix gives update on its testing of retinal replacement therapy with AAGP

Aerie reports phase III topline results from MERCURY 2 study of Roclatan

Protagonist Therapeutics receives SBIR grant to develop biomarkers of IL-23R antagonist activity

FDA grants priority review to sBLA for Opdivo in previously treated HCC

Concert Pharmaceuticals shareholders approve CTP-656 asset purchase agreement with Vertex

Mundipharma launches Mundesine in Japan

Phase II study evaluates oral levosimendan in amyotrophic lateral sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...